查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1414941

全球神經病變疼痛市場：按藥物類別、適應症和分銷管道 - 機會分析和行業預測，2022-2032

Neuropathic Pain Market By Drug class, By Indication, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2022-2032
出版日期: | 出版商: Allied Market Research | 英文 279 Pages | 商品交期: 2-3個工作天內

價格

預計2022年全球神經病變疼痛市場規模將達77億美元，2022年至2032年複合年成長率為5.6%，2032年將達133億美元。

神經病變疼痛市場按藥物類別、適應症、分銷管道和地區進行細分。

神經病理性疼痛市場-IMG1

相關利益者的主要利益

  • 本報告定量分析了 2022 年至 2032 年神經病變疼痛市場的細分市場、當前趨勢、估計和動態，並確定了一般神經病變疼痛市場的機會。
  • 我們提供市場研究以及與市場促進因素、市場抑制因素和市場機會相關的資訊。
  • 波特的五力分析強調買家和相關利益者幫助利害關係人做出利潤驅動的商業決策並加強供應商-買家網路的力量。
  • 對神經病變疼痛市場細分的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前地位的清晰了解。
  • 該報告包括對區域和全球神經病變疼痛市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 神經病變疼痛加劇
      • 慢性病增加
      • 老年人口增加
    • 抑制因素
      • 神經病變疼痛藥物的副作用
    • 機會
      • 正在研發的藥物數量增加

第4章神經病變疼痛市場：依藥物類別

  • 概述
  • 抗憂鬱症
  • 抗驚厥藥
  • 鴉片類藥物
  • 辣椒素
  • 其他

第5章神經病變疼痛市場：依適應症分類

  • 概述
  • 糖尿病神經病變
  • 脊椎狹窄
  • 化療引起的周邊神經病變
  • 其他

第6章神經病變疼痛市場：依分銷管道

  • 概述
  • 醫院藥房
  • 藥局/零售藥房
  • 網路藥房

第7章神經病變疼痛市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他亞太地區
  • 拉丁美洲、中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他拉丁美洲、中東/非洲

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Mallinckrodt Pharmaceuticals
  • Eli Lilly and Company.
  • Grunenthal GmbH.
  • Collegium Pharmaceutical Inc
  • Sun Pharmaceutical Industries Ltd.
  • Abbott Laboratories
Product Code: A05082

According to a new report published by Allied Market Research, titled, "Neuropathic Pain Market," The neuropathic pain market was valued at $7.7 billion in 2022, and is estimated to reach $13.3 billion by 2032, growing at a CAGR of 5.6% from 2022 to 2032. The neuropathic pain market is segmented on the basis of drug class, indication, distribution channel, and region.

Neuropathic Pain Market - IMG1

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuropathic pain market analysis from 2022 to 2032 to identify the prevailing neuropathic pain market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the neuropathic pain market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global neuropathic pain market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.
  • Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Go To Market Strategy
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Brands Share Analysis
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Drug class

  • Antidepressants
    • Type
    • Tricyclic Antidepressants
    • Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
  • Anticonvulsant
  • Opioids
  • Capsaicin
  • Others

By Indication

  • Diabetic Neuropathy
  • Spinal Stenosis
  • Chemotherapy-Induced Peripheral Neuropathy
  • Others

By Distribution channel

  • Hospital Pharmacies
  • Drugs Stores and Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • Teva Pharmaceuticals
    • Novartis AG
    • Eli Lilly and Company.
    • Mallinckrodt Pharmaceuticals
    • Collegium Pharmaceutical Inc
    • Sun Pharmaceutical Industries Ltd.
    • Abbott Laboratories
    • Glenmark Pharmaceuticals Limited
    • Grunenthal GmbH.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in cases of neuropathic pain
      • 3.4.1.2. Rise in prevalence of chronic diseases
      • 3.4.1.3. Rise in geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects of neuropathic pain medicine
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in number of drugs in pipeline

CHAPTER 4: NEUROPATHIC PAIN MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Antidepressants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Antidepressants Neuropathic Pain Market by Type
  • 4.3. Anticonvulsant
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Opioids
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Capsaicin
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: NEUROPATHIC PAIN MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Diabetic Neuropathy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Spinal Stenosis
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Chemotherapy-Induced Peripheral Neuropathy
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drugs Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: NEUROPATHIC PAIN MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Drug class
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Drug class
      • 7.2.5.1.2. Market size and forecast, by Indication
      • 7.2.5.1.3. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Drug class
      • 7.2.5.2.2. Market size and forecast, by Indication
      • 7.2.5.2.3. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Drug class
      • 7.2.5.3.2. Market size and forecast, by Indication
      • 7.2.5.3.3. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Drug class
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Drug class
      • 7.3.5.1.2. Market size and forecast, by Indication
      • 7.3.5.1.3. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Drug class
      • 7.3.5.2.2. Market size and forecast, by Indication
      • 7.3.5.2.3. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Drug class
      • 7.3.5.3.2. Market size and forecast, by Indication
      • 7.3.5.3.3. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Drug class
      • 7.3.5.4.2. Market size and forecast, by Indication
      • 7.3.5.4.3. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Drug class
      • 7.3.5.5.2. Market size and forecast, by Indication
      • 7.3.5.5.3. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Drug class
      • 7.3.5.6.2. Market size and forecast, by Indication
      • 7.3.5.6.3. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Drug class
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Drug class
      • 7.4.5.1.2. Market size and forecast, by Indication
      • 7.4.5.1.3. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Drug class
      • 7.4.5.2.2. Market size and forecast, by Indication
      • 7.4.5.2.3. Market size and forecast, by Distribution channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Market size and forecast, by Drug class
      • 7.4.5.3.2. Market size and forecast, by Indication
      • 7.4.5.3.3. Market size and forecast, by Distribution channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Market size and forecast, by Drug class
      • 7.4.5.4.2. Market size and forecast, by Indication
      • 7.4.5.4.3. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Drug class
      • 7.4.5.5.2. Market size and forecast, by Indication
      • 7.4.5.5.3. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Drug class
      • 7.4.5.6.2. Market size and forecast, by Indication
      • 7.4.5.6.3. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Drug class
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Drug class
      • 7.5.5.1.2. Market size and forecast, by Indication
      • 7.5.5.1.3. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Drug class
      • 7.5.5.2.2. Market size and forecast, by Indication
      • 7.5.5.2.3. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Drug class
      • 7.5.5.3.2. Market size and forecast, by Indication
      • 7.5.5.3.3. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Drug class
      • 7.5.5.4.2. Market size and forecast, by Indication
      • 7.5.5.4.3. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Pfizer Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Teva Pharmaceuticals
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Glenmark Pharmaceuticals Limited
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Mallinckrodt Pharmaceuticals
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Eli Lilly and Company.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Grunenthal GmbH.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Collegium Pharmaceutical Inc
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Sun Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Abbott Laboratories
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. NEUROPATHIC PAIN MARKET FOR ANTIDEPRESSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL ANTIDEPRESSANTS NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. NEUROPATHIC PAIN MARKET FOR ANTICONVULSANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. NEUROPATHIC PAIN MARKET FOR OPIOIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. NEUROPATHIC PAIN MARKET FOR CAPSAICIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. NEUROPATHIC PAIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 09. NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NEUROPATHIC PAIN MARKET FOR SPINAL STENOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NEUROPATHIC PAIN MARKET FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NEUROPATHIC PAIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 14. NEUROPATHIC PAIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NEUROPATHIC PAIN MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NEUROPATHIC PAIN MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NEUROPATHIC PAIN MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 22. U.S. NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 23. U.S. NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 24. U.S. NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. CANADA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 26. CANADA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. UK NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 42. UK NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 43. UK NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. ITALY NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 45. ITALY NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 46. ITALY NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. CHINA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 61. CHINA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 62. CHINA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. INDIA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 67. INDIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 68. INDIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 77. LAMEA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. LAMEA NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 81. BRAZIL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 83. SAUDI ARABIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 84. SAUDI ARABIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. PFIZER INC.: KEY EXECUTIVES
  • TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 95. TEVA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 96. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 97. TEVA PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 98. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 99. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 100. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 101. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 102. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 103. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 105. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 107. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 108. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 109. MALLINCKRODT PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 110. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 111. ELI LILLY AND COMPANY.: KEY EXECUTIVES
  • TABLE 112. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 113. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
  • TABLE 114. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 115. ELI LILLY AND COMPANY.: KEY STRATERGIES
  • TABLE 116. GRUNENTHAL GMBH.: KEY EXECUTIVES
  • TABLE 117. GRUNENTHAL GMBH.: COMPANY SNAPSHOT
  • TABLE 118. GRUNENTHAL GMBH.: PRODUCT SEGMENTS
  • TABLE 119. GRUNENTHAL GMBH.: PRODUCT PORTFOLIO
  • TABLE 120. GRUNENTHAL GMBH.: KEY STRATERGIES
  • TABLE 121. COLLEGIUM PHARMACEUTICAL INC: KEY EXECUTIVES
  • TABLE 122. COLLEGIUM PHARMACEUTICAL INC: COMPANY SNAPSHOT
  • TABLE 123. COLLEGIUM PHARMACEUTICAL INC: PRODUCT SEGMENTS
  • TABLE 124. COLLEGIUM PHARMACEUTICAL INC: PRODUCT PORTFOLIO
  • TABLE 125. COLLEGIUM PHARMACEUTICAL INC: KEY STRATERGIES
  • TABLE 126. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 127. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 130. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 131. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 132. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 133. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. NEUROPATHIC PAIN MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF NEUROPATHIC PAIN MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN NEUROPATHIC PAIN MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN NEUROPATHIC PAIN MARKET (2022-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL NEUROPATHIC PAIN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR ANTIDEPRESSANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR ANTICONVULSANT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR OPIOIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR CAPSAICIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. NEUROPATHIC PAIN MARKET, BY INDICATION, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR SPINAL STENOSIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. NEUROPATHIC PAIN MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 27. U.S. NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CANADA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MEXICO NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. GERMANY NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. FRANCE NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. ITALY NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF EUROPE NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. JAPAN NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. AUSTRALIA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. INDIA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. BRAZIL NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SAUDI ARABIA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF LAMEA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50. COMPETITIVE DASHBOARD
  • FIGURE 51. COMPETITIVE HEATMAP: NEUROPATHIC PAIN MARKET
  • FIGURE 52. TOP PLAYER POSITIONING, 2022
  • FIGURE 53. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. TEVA PHARMACEUTICALS: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 57. TEVA PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 58. TEVA PHARMACEUTICALS: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 59. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 60. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. MALLINCKRODT PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. GRUNENTHAL GMBH.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. GRUNENTHAL GMBH.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. GRUNENTHAL GMBH.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. COLLEGIUM PHARMACEUTICAL INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 74. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 75. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 76. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 77. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)